Publication of the results of the Valbiotis REVERSE-IT study

Valbiotis, a laboratory specializing in cardiometabolic health, announces that the results of its REVERSE-IT clinical trial of Totum•63 have been published in Nature Communications. This publication marks international recognition, validating the scientific quality of the study. Conducted in 52 European centers, it reveals a significant decrease in fasting blood glucose after 6 months of using Totum•63. Participants also showed improvements in various cardiometabolic parameters.

The study involved 636 participants with prediabetes or recently diagnosed type 2 diabetes who did not require immediate treatment. Totum•63, rich in plant-based polyphenols, proved effective with an excellent tolerability profile. This recognition reinforces Valbiotis' credibility in developing solutions based on robust clinical evidence.